{"id":5959,"date":"2022-07-11T15:30:47","date_gmt":"2022-07-11T12:30:47","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5959"},"modified":"2022-07-12T22:32:46","modified_gmt":"2022-07-12T19:32:46","slug":"ttb-udek-uyesi-derneklerin-covid-19-asisi-hatirlatma-dozu-hakkinda-gorusu","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/ttb-udek-uyesi-derneklerin-covid-19-asisi-hatirlatma-dozu-hakkinda-gorusu\/","title":{"rendered":"TTB UDEK \u00dcyesi Derneklerin COVID-19 A\u015f\u0131s\u0131 Hat\u0131rlatma Dozu Hakk\u0131nda G\u00f6r\u00fc\u015f\u00fc"},"content":{"rendered":"

\"\"T\u00fcrkiye ve d\u00fcnyada COVID-19 hastalar\u0131n\u0131n say\u0131s\u0131 h\u0131zla artarken Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 50 ya\u015f \u00fcst\u00fc ve risk grubundakilerin son a\u015f\u0131lar\u0131n\u0131n \u00fczerinden alt\u0131 ay ge\u00e7mi\u015fse hat\u0131rlatma dozu yapt\u0131rmalar\u0131 gerekti\u011fini belirtti. Bu gruptakilere MHRS a\u015f\u0131 randevular\u0131 a\u00e7\u0131ld\u0131. Bizler TTB UDEK Y\u00fcr\u00fctme Kurulu ve UDEK \u00fcyesi dernekler, KL\u0130M\u0130K taraf\u0131ndan haz\u0131rlanan ve ortakla\u015ft\u0131r\u0131lan g\u00f6r\u00fc\u015flerimizi kamuoyu ile payla\u015f\u0131yoruz.<\/strong><\/p>\n

    \n
  1. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/li>\n
  2. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong>\u00a0Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozunu (yap\u0131labiliyorsa BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/li>\n
  3. \u00c7e\u015fitli nedenlerle primer a\u015f\u0131 \u015femas\u0131 (Sinovac i\u00e7in 0,1, 4. aylarda 3 doz, BioNTech i\u00e7in bir ay arayla iki doz) yar\u0131m kalan ki\u015filerin a\u015f\u0131lamalar\u0131na kald\u0131klar\u0131 yerden devam edilmesi, hat\u0131rlatma dozlar\u0131n\u0131n primer \u015feman\u0131n tamamlanmas\u0131ndan en erken 3 ay sonra yap\u0131lmas\u0131 \u00f6nerilir.<\/li>\n
  4. \u0130ki doz BioNTech a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin 2. dozdan en erken 3 ay sonra hat\u0131rlatma dozunu olmalar\u0131 \u00f6nerilir.<\/li>\n
  5. \u00dc\u00e7 doz Sinovac a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin son dozdan en erken 3 ay sonra hat\u0131rlatma dozlar\u0131n\u0131 (tercihen BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/li>\n
  6. \u0130ki doz Sinovac ard\u0131ndan bir doz BioNTech a\u015f\u0131s\u0131 olanlar\u0131n, son a\u015f\u0131dan en erken 3 ay sonra ikinci doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/li>\n
  7. \u0130ki doz Sinovac ard\u0131ndan iki doz BioNTech a\u015f\u0131s\u0131 (toplam 4 doz a\u015f\u0131) olanlar i\u00e7erisinde 50 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  8. Daha \u00f6nce \u00fc\u00e7 doz BioNTech a\u015f\u0131s\u0131 olanlar i\u00e7erisinde 50 ya\u015f\u0131n \u00fczerinde olanlar, hastal\u0131k veya ilaca ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar, altta yatan ciddi hastal\u0131\u011f\u0131 (diyaliz uygulananlar, kalp yetmezli\u011fi, ileri AC yetmezli\u011fi ve siroz) bulunanlar ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan en erken\u00a0 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerde a\u015f\u0131lar\u0131n a\u011f\u0131r hastal\u0131k ve \u00f6l\u00fcmden koruyucu etkisi devam etti\u011finden hat\u0131rlatma dozunu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. \u00d6neriler, yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  9. \u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz BioNTech olmu\u015f ki\u015filere, Omikrona ve di\u011fer varyantlara kar\u015f\u0131 uzun s\u00fcre korunduklar\u0131 i\u00e7in, \u015fimdiki bilgilere g\u00f6re ek hat\u0131rlatma dozuna gerek yoktur. Yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  10. \u00d6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irdikten sonra bir doz Sinovac olanlar\u0131n, son Sinovac\u2019tan 3 ay sonra (tercihen BioNTech ile) bir hat\u0131rlatma dozu olmalar\u0131 \u00f6nerilir.<\/li>\n
  11. \u0130ki doz BioNTech olmas\u0131na ra\u011fmen herhangi bir varyantla hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin hastal\u0131ktan 6 ay sonra bir doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. B\u00f6ylelikle a\u015f\u0131 sonras\u0131nda Omikrona kar\u015f\u0131 en az 6 ay yeterli koruma sa\u011flanacakt\u0131r.\u00a0 Bu ki\u015filerin yeni bir varyant \u00e7\u0131kmad\u0131\u011f\u0131 s\u00fcrece hat\u0131rlatma dozu olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. Alt\u0131nc\u0131 ay\u0131n sonunda yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  12. A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan \u00f6nceki varyantlarla (\u00fclkemiz i\u00e7in 1 Ocak 2022 \u00f6ncesinde) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin, hastal\u0131ktan en erken 3 ay sonra (tercihen 6. Ayda) tek doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131, mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong>\u00a0iki doz Sinovac a\u015f\u0131s\u0131 ile (0 ve 1. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/li>\n
  13. A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan Omikron ile (\u00fclkemiz i\u00e7in 1 Ocak 2022 sonras\u0131nda) hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin (Delta varyant\u0131na yeterli ba\u011f\u0131\u015f\u0131kl\u0131klar\u0131 olmayaca\u011f\u0131 i\u00e7in) hastal\u0131ktan 3 ay sonra ba\u015flamak \u00fczere 1 ay arayla iki doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir. mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong>\u00a0Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/li>\n
  14. \u0130ki doz Sinovac ard\u0131ndan 2 doz BioNTech a\u015f\u0131s\u0131 veya 3 doz BioNTech a\u015f\u0131s\u0131 \u00a0veya 4 doz BioNTech a\u015f\u0131s\u0131 uyguland\u0131ktan sonra COVID-19 ge\u00e7irmi\u015f ki\u015filere hat\u0131rlatma dozu yap\u0131lmas\u0131na eldeki verilere g\u00f6re gerek yoktur.<\/li>\n
  15. Ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filerin inaktif a\u015f\u0131 yerine mRNA a\u015f\u0131lar\u0131 ile a\u015f\u0131lanmalar\u0131 \u00f6nerilir. Bu ki\u015filer 1 ay arayla 3 dozdan (BioNTech) olu\u015fan primer a\u015f\u0131 \u015femas\u0131n\u0131 tamamlad\u0131ktan 3 ay sonra birinci ek dozlar\u0131n\u0131 (4. a\u015f\u0131lar\u0131n\u0131) , bundan en az 4 ay sonra da ikinci ek dozlar\u0131n\u0131 (5. a\u015f\u0131lar\u0131n\u0131) olmal\u0131d\u0131rlar. Bundan farkl\u0131 \u015femalar uygulanm\u0131\u015f ise ek dozlar\u0131n say\u0131s\u0131 ve zamanlamas\u0131n\u0131n belirlenmesi i\u00e7in \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji uzmanlar\u0131na ba\u015fvurmalar\u0131 \u00f6nerilir.<\/li>\n
  16. \u00d6zellikle >65 ya\u015fta ve sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131nda,\u00a0 d\u00f6rt doz BioNTech veya iki doz SinoVac+3 doz BioNTech a\u015f\u0131lamas\u0131ndan sonra, \u00a0ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olmad\u0131\u011f\u0131 s\u00fcrece bir hat\u0131rlatma dozu daha yap\u0131lmas\u0131 \u00a0veya yap\u0131lmamas\u0131\u00a0 konusunda \u00f6neri yapabilecek yeterli veri bulunmamaktad\u0131r. Bu ki\u015filerde varyantlar\u0131 da i\u00e7eren polivalan a\u015f\u0131larla ek dozlar\u0131n gereklili\u011fi, \u00a0\u00a0etkinli\u011fi ve g\u00fcvenilirli\u011fi konusunda \u00e7al\u0131\u015fmalar devam etmektedir, bu \u00e7al\u0131\u015fmalar\u0131n sonu\u00e7lanmas\u0131ndan ve yeni i\u00e7erikli a\u015f\u0131lar\u0131n \u00fcretilmesinden sonra, muhtemelen sonbaharda \u00a0yeni\u00a0 \u00f6neriler yap\u0131labilecektir. \u00a0Ek olarak \u00fclkemizde, a\u015f\u0131lama \u015femalar\u0131na g\u00f6re \u00a0etkililik oranlar\u0131n\u0131n a\u00e7\u0131klanmas\u0131 da daha ak\u0131lc\u0131 kararlar\u0131n al\u0131nmas\u0131n\u0131 sa\u011flayacakt\u0131r.<\/li>\n
  17. \u00dclkemizde gerek primer a\u015f\u0131lamas\u0131, \u00a0gerekse\u00a0\u00a0 hat\u0131rlatma dozu\/dozlar\u0131\u00a0 yap\u0131lm\u0131\u015f ki\u015fi say\u0131s\u0131n\u0131n yetersizli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, bu gruplar\u0131n a\u015f\u0131lanmas\u0131n\u0131n sa\u011flanmas\u0131 i\u00e7in kampanyalar d\u00fczenlenmesi ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n bu konuda \u00f6zel \u00e7aba g\u00f6stermesi, <12 ya\u015f \u00e7ocuklar i\u00e7in uygun a\u015f\u0131lar\u0131n sa\u011flanarak a\u015f\u0131laman\u0131n ba\u015flanmas\u0131, \u00a0ek olarak maske kullan\u0131m\u0131 gibi a\u015f\u0131 d\u0131\u015f\u0131 \u00f6nlemlerin de uygulamaya konulmas\u0131 ya\u015famakta oldu\u011fumuz son omikron dalgas\u0131nda \u00f6l\u00fcmlerin azalt\u0131lmas\u0131nda en etkili \u00f6nlem olacakt\u0131r.<\/li>\n
  18. A\u015f\u0131lama kampanyalar\u0131nda a\u015f\u0131 randevular\u0131n\u0131n aksaks\u0131z y\u00fcr\u00fct\u00fclmesi, a\u015f\u0131 s\u00fcreklili\u011finin\u00a0 ve di\u011fer lojistik desteklerin sa\u011flanmas\u0131n\u0131n kritik \u00f6nemi unutulmamal\u0131d\u0131r.<\/li>\n
  19. A\u011f\u0131r ruhsal hastal\u0131\u011f\u0131 olanlarda kalp hastal\u0131\u011f\u0131, kronik akci\u011fer hastal\u0131\u011f\u0131 gibi ek hastal\u0131k oranlar\u0131n\u0131n y\u00fcksek olmas\u0131, bili\u015fsel ve sosyal zorluklar nedeniyle a\u015f\u0131ya eri\u015fimde dezavantajl\u0131 grup olmalar\u0131 nedeniyle bu hastalarda eksik a\u015f\u0131laman\u0131n tamamlanmas\u0131, hat\u0131rlatma dozunun yapt\u0131r\u0131lmas\u0131 te\u015fvik edilmelidir.<\/li>\n<\/ol>\n

    Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    T\u00fcrkiye ve d\u00fcnyada COVID-19 hastalar\u0131n\u0131n say\u0131s\u0131 h\u0131zla artarken Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 50 ya\u015f \u00fcst\u00fc ve risk grubundakilerin son a\u015f\u0131lar\u0131n\u0131n \u00fczerinden alt\u0131 ay ge\u00e7mi\u015fse hat\u0131rlatma dozu yapt\u0131rmalar\u0131 gerekti\u011fini belirtti. Bu gruptakilere MHRS a\u015f\u0131 randevular\u0131 a\u00e7\u0131ld\u0131. Bizler TTB UDEK Y\u00fcr\u00fctme Kurulu ve UDEK \u00fcyesi dernekler, KL\u0130M\u0130K taraf\u0131ndan haz\u0131rlanan ve ortakla\u015ft\u0131r\u0131lan g\u00f6r\u00fc\u015flerimizi kamuoyu ile payla\u015f\u0131yoruz. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*\u00a0Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozunu (yap\u0131labiliyorsa BioNTech a\u015f\u0131s\u0131 […]<\/p>\n","protected":false},"author":4,"featured_media":5961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5959"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5959"}],"version-history":[{"count":1,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5959\/revisions"}],"predecessor-version":[{"id":5960,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5959\/revisions\/5960"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5961"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}